Assenagon Asset Management S.A. Purchases 328,312 Shares of AC Immune SA (NASDAQ:ACIU)

Assenagon Asset Management S.A. lifted its holdings in AC Immune SA (NASDAQ:ACIU - Free Report) by 294.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 439,730 shares of the company's stock after purchasing an additional 328,312 shares during the period. Assenagon Asset Management S.A. owned about 0.44% of AC Immune worth $1,755,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ACIU. Nixon Peabody Trust Co. bought a new position in AC Immune during the fourth quarter valued at approximately $64,000. Platinum Investment Management Ltd. boosted its position in AC Immune by 14.6% in the fourth quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company's stock valued at $7,578,000 after buying an additional 193,123 shares in the last quarter. Avidity Partners Management LP grew its position in AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company's stock worth $22,345,000 after acquiring an additional 1,499,280 shares during the last quarter. BVF Inc. IL increased its stake in shares of AC Immune by 96.2% in the fourth quarter. BVF Inc. IL now owns 14,571,236 shares of the company's stock valued at $72,856,000 after buying an additional 7,142,857 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of AC Immune by 96.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company's stock worth $56,000 after purchasing an additional 9,334 shares in the last quarter. Institutional investors own 51.36% of the company's stock.

AC Immune Price Performance

Shares of NASDAQ ACIU traded down $0.30 during mid-day trading on Thursday, hitting $3.06. 237,486 shares of the stock traded hands, compared to its average volume of 433,801. The company has a market cap of $302.14 million, a PE ratio of -4.54 and a beta of 1.27. The firm has a 50 day simple moving average of $3.74 and a two-hundred day simple moving average of $3.39. AC Immune SA has a twelve month low of $2.20 and a twelve month high of $5.14.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ACIU. StockNews.com raised AC Immune from a "sell" rating to a "hold" rating in a research note on Wednesday, May 8th. BTIG Research assumed coverage on shares of AC Immune in a research report on Friday, May 31st. They issued a "buy" rating and a $8.00 target price for the company.

AC Immune Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.